Table 2 Comparative analysis of clinical and therapeutic parameters according to the subsequent achievement of VRE negative conversion.
Subsequent achievement of VRE negative conversion | p-value | ||
|---|---|---|---|
Yes (n = 39) | No (n = 83) | ||
Male:Female (n) | 23:16 | 50:33 | 0.8941 |
Age (years)* | 71.9 ± 12.4 years | 72.1 ± 14.0 years | 0.9552 |
Body mass index at hospitalization* | 23.22 ± 4.85 | 21.93 ± 4.09 | 0.1491 |
Serum albumin level at hospitalization* | 3.37 ± 0.85 g/dL | 3.02 ± 0.79 g/dL | 0.0310 |
Past medical history | |||
Diabetes mellitus, n (%) | 10 (25.6%) | 28 (33.7%) | 0.3680 |
Hypertension, n (%) | 17 (43.6%) | 33 (39.8%) | 0.6883 |
Dyslipidemia, n (%) | 7 (17.9%) | 6 (7.2%) | 0.1125 |
Details of treatment after admission before VRE detection | |||
Perioperative case (n; surgery after admission [%]) | 10 (25.6%) | 18 (21.7%) | 0.6281 |
Use of antibiotics (total; n [%]) | 34 (87.2%) | 76 (91.6%) | 0.5186 |
Use of antibiotics (VCM; n [%]) | 6 (15.4%) | 20 (24.1%) | 0.3466 |
Use of a nasogastric feeding tube, n (%) | 21 (53.8%) | 33 (39.8%) | 0.1440 |
Details of the treatment for VRE | |||
Probiotics, n (%) | 29 (74.4%) | 40 (48.2%) | 0.0065 |
Total Kampo medicines, n (%) | 13 (33.3%) | 5 (6.0%) | 0.0002 |
Hochuekkito, n (%) | 11 (28.2%) | 5 (6.0%) | 0.0014 |
